Respiratory Distress Syndrome clinical trials at UC Irvine
2 in progress, 1 open to eligible people
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
open to eligible people ages 18 years and up
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio ≤150) due to pneumonia or other infections. Potential subjects hospitalized with pneumonia or other infections are to be screened within 24 hours of diagnosis of ARDS.
Irvine, California and other locations
Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants
Sorry, in progress, not accepting new patients
This study is being conducted to determine whether prophylactic administration of surfactant by the Less Invasive Surfactant Administration (LISA) method reduces the need for mechanical ventilation in the first 72 hours of life when compared to early Continuous Positive Airway Pressure (CPAP) alone.
Irvine, California and other locations
Our lead scientists for Respiratory Distress Syndrome research studies include Alpesh Amin, MD.
Last updated: